Calquence Tablet, Film Coated
Product Images NDC 0310-3512

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Calquence (NDC 0310-3512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100mg_60_tablet_bottle (100mg 60 Tablets Bottle)

100mg_60_tablet_bottle (100mg 60 Tablets Bottle)
CALQUENCE 100 mg (acalabrutinib) tablets label for oral use. The label states prescription use only and includes warnings not to chew, crush, dissolve, or cut tablets. Manufactured for AstraZeneca Pharmaceuticals LP, Wilmington, DE, and by AstraZeneca AB, Sweden. The package contains 60 film-coated tablets.*
FDA Label Image

Chemical_structure (Chemical Structure)

Chemical_structure (Chemical Structure)
Chemical structure diagram of acalabrutinib, the active ingredient in CALQUENCE 100 mg tablets. The molecular structure shows interconnected rings and functional groups characteristic of the compound.*
FDA Label Image

Figure_1 (Figure 1)

Figure_1 (Figure 1)
A Kaplan-Meier survival curve chart showing progression-free survival (%) over time in months for three treatment groups: CALQUENCE + Obinutuzumab, CALQUENCE alone, and Chlorambucil + Obinutuzumab. The graph includes censored data points and a table beneath presenting the number of patients at risk at different time intervals for each group.*
FDA Label Image

Figure_2 (Figure 2)

Figure_2 (Figure 2)
A Kaplan-Meier survival curve comparing progression-free survival percentages over months for CALQUENCE tablets 100 mg versus IR or BR treatments. The graph shows survival percentages on the vertical axis and time in months on the horizontal axis, with separate lines for CALQUENCE and IR or BR, including censored data points and a table of number at risk by month below the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.